HC Wainwright Issues Positive Forecast for Genmab A/S (NASDAQ:GMAB) Stock Price

Key Points

• HC Wainwright has raised its price target for Genmab A/S (NASDAQ:GMAB) from $36.00 to $40.00, suggesting a potential upside of 25.48% from the stock's previous close and maintaining a "buy" rating.
• Genmab A/S's latest quarterly earnings report revealed $0.54 earnings per share, which surpassed analysts' expectations of $0.39, while revenue came in at $925 million.
• Institutional investors have shown significant interest, with several firms increasing their holdings in Genmab A/S, indicating growing confidence in the company's prospects.

Genmab A/S (NASDAQ:GMAB - Get Free Report) had its price objective hoisted by equities research analysts at HC Wainwright from $36.00 to $40.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. HC Wainwright's target price would indicate a potential upside of 25.48% from the stock's previous close.

Several other brokerages have also weighed in on GMAB. Wall Street Zen raised shares of Genmab A/S from a "buy" rating to a "strong-buy" rating in a research report on Friday, September 26th. Zacks Research cut Genmab A/S from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, August 19th. Guggenheim raised Genmab A/S from a "neutral" rating to a "buy" rating and set a $43.00 price objective for the company in a research report on Tuesday, September 23rd. Finally, Truist Financial raised their target price on Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a research report on Tuesday, July 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $40.80.

Genmab A/S Trading Up 0.3%

GMAB stock traded up $0.11 during trading on Thursday, hitting $31.88. The company had a trading volume of 259,349 shares, compared to its average volume of 1,487,815. The firm has a market capitalization of $20.45 billion, a price-to-earnings ratio of 16.04, a P/E/G ratio of 1.75 and a beta of 0.98. The business has a 50 day moving average of $25.47 and a 200 day moving average of $22.26. Genmab A/S has a fifty-two week low of $17.24 and a fifty-two week high of $32.24.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Thursday, August 7th. The company reported $0.54 earnings per share for the quarter, beating analysts' consensus estimates of $0.39 by $0.15. The company had revenue of $925.00 million during the quarter, compared to the consensus estimate of $5.77 billion. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. Genmab A/S has set its FY 2025 guidance at EPS. As a group, equities analysts predict that Genmab A/S will post 1.45 EPS for the current year.

Hedge Funds Weigh In On Genmab A/S

Several institutional investors have recently modified their holdings of GMAB. Headlands Technologies LLC raised its position in Genmab A/S by 1,525.0% in the 1st quarter. Headlands Technologies LLC now owns 1,560 shares of the company's stock valued at $31,000 after buying an additional 1,464 shares during the last quarter. Osaic Holdings Inc. raised its stake in shares of Genmab A/S by 37.8% during the 2nd quarter. Osaic Holdings Inc. now owns 1,603 shares of the company's stock worth $33,000 after purchasing an additional 440 shares in the last quarter. CWM LLC increased its holdings in shares of Genmab A/S by 50.5% during the 2nd quarter. CWM LLC now owns 1,797 shares of the company's stock worth $37,000 after acquiring an additional 603 shares during the last quarter. Caitong International Asset Management Co. Ltd grew its holdings in Genmab A/S by 124.3% in the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,931 shares of the company's stock valued at $38,000 after buying an additional 1,070 shares in the last quarter. Finally, EverSource Wealth Advisors LLC lifted its position in shares of Genmab A/S by 124.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,114 shares of the company's stock valued at $44,000 after acquiring an additional 1,174 shares during the period. Institutional investors own 7.07% of the company's stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.